Advanced

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

Chalmers, J. R.; Schmitt, J.; Apfelbacher, C.; Dohil, M.; Eichenfield, L. F.; Simpson, E. L.; Singh, J.; Spuls, P.; Thomas, K. S. and Admani, S., et al. (2014) In British Journal of Dermatology 171(6). p.1318-1325
Abstract
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should... (More)
This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Dermatology
volume
171
issue
6
pages
1318 - 1325
publisher
Wiley-Blackwell
external identifiers
  • wos:000347236100172
  • scopus:84908096132
ISSN
1365-2133
DOI
10.1111/bjd.13237
language
English
LU publication?
yes
id
03f47d13-3264-4277-bbd1-192794b8b744 (old id 5081895)
date added to LUP
2015-03-02 07:09:02
date last changed
2017-11-05 03:07:31
@article{03f47d13-3264-4277-bbd1-192794b8b744,
  abstract     = {This report provides a summary of the third meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in San Diego, CA, U.S.A., 6-7 April 2013 (HOME III). The meeting addressed the four domains that had previously been agreed should be measured in every eczema clinical trial: clinical signs, patient-reported symptoms, long-term control and quality of life. Formal presentations and nominal group techniques were used at this working meeting, attended by 56 voting participants (31 of whom were dermatologists). Significant progress was made on the domain of clinical signs. Without reference to any named scales, it was agreed that the intensity and extent of erythema, excoriation, oedema/papulation and lichenification should be included in the core outcome measure for the scale to have content validity. The group then discussed a systematic review of all scales measuring the clinical signs of eczema and their measurement properties, followed by a consensus vote on which scale to recommend for inclusion in the core outcome set. Research into the remaining three domains was presented, followed by discussions. The symptoms group and quality of life groups need to systematically identify all available tools and rate the quality of the tools. A definition of long-term control is needed before progress can be made towards recommending a core outcome measure.},
  author       = {Chalmers, J. R. and Schmitt, J. and Apfelbacher, C. and Dohil, M. and Eichenfield, L. F. and Simpson, E. L. and Singh, J. and Spuls, P. and Thomas, K. S. and Admani, S. and Aoki, V. and Ardeleanu, M. and Barbarot, S. and Berger, T. and Bergman, J. N. and Block, J. and Borok, N. and Burton, T. and Chamlin, S. L. and Deckert, S. and DeKlotz, C. C. and Graff, L. B. and Hanifin, J. M. and Hebert, A. A. and Humphreys, R. and Katoh, N. and Kisa, R. M. and Margolis, D. J. and Merhand, S. and Minnillo, R. and Mizutani, H. and Nankervis, H. and Ohya, Y. and Rodgers, P. and Schram, M. E. and Stalder, J. F. and Svensson, Åke and Takaoka, R. and Teper, A. and Tom, W. L. and von Kobyletzki, Laura and Weisshaar, E. and Zelt, S. and Williams, H. C.},
  issn         = {1365-2133},
  language     = {eng},
  number       = {6},
  pages        = {1318--1325},
  publisher    = {Wiley-Blackwell},
  series       = {British Journal of Dermatology},
  title        = {Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)},
  url          = {http://dx.doi.org/10.1111/bjd.13237},
  volume       = {171},
  year         = {2014},
}